RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...
Stiolto Respimat received approval from the Food and Drug Administration (FDA) in May 2015. The Respimat inhaler actively delivers a slow-moving mist that aids the patient independent of inspiratory ...
In the PHYSACTO trial, exercise capacity was measured by the length of time people with COPD could walk in an Endurance Shuttle Walking Test, which measures how far someone can walk at a standard ...
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...
FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Stiolto Respimat for the once-daily maintenance treatment in patients with COPD as well as ...
Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for the long-term maintenance treatment of ...
INDIANAPOLIS & RIDGEFIELD, Conn.--(BUSINESS WIRE)--The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to ...
Taking a deep breath can be hard for COPD patients. The irony is, that's exactly what they often need to do to release their medicine from inhalers. That's why Boehringer Ingelheim’s latest ad ...
FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback